Drug Trial Radar · NCT07196501
A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
550
Planned (sponsor's estimate)
Start
Aug 18, 2025
Primary completion
Jul 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Sep 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of osavampator (previously NBI-1065845) compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.
Conditions
- Major Depressive Disorder
Interventions
OsavampatorDrug
Oral tablet
PlaceboDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from Randomization to RelapseTime frame: From randomization to the earliest of relapse or end-of study (up to approximately 32 months)
Locations
61 sites in 11 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Oceanside, California · Recruiting
Neurocrine Clinical Site
Orange, California · Recruiting
Neurocrine Clinical Site
San Jose, California · Recruiting
Neurocrine Clinical Site
New Haven, Connecticut · Recruiting
Neurocrine Clinical Site
Miami Gardens, Florida · Recruiting
Neurocrine Clinical Site
Orlando, Florida · Recruiting
Neurocrine Clinical Site
Palm Bay, Florida · Recruiting
Neurocrine Clinical Site
Tampa, Florida · Recruiting
Neurocrine Clinical Site
Iowa City, Iowa · Recruiting
Neurocrine Clinical Site
Marrero, Louisiana · Recruiting
Neurocrine Clinical Site
O'Fallon, Missouri · Recruiting
Neurocrine Clinical Site
Albuquerque, New Mexico · Active not recruiting
Neurocrine Clinical Site
Glen Oaks, New York · Recruiting
Neurocrine Clinical Site
Charlotte, North Carolina · Recruiting
Neurocrine Clinical Site
Edmond, Oklahoma · Recruiting
Neurocrine Clinical Site
Oklahoma City, Oklahoma · Recruiting
Neurocrine Clinical Site
Philadelphia, Pennsylvania · Recruiting
Neurocrine Clinical Site
Austin, Texas · Active not recruiting
Neurocrine Clinical Site
Bellaire, Texas · Recruiting
Neurocrine Clinical Site
Friendswood, Texas · Terminated
Neurocrine Clinical Site
Stafford, Texas · Recruiting
Neurocrine Clinical Site
Wichita Falls, Texas · Active not recruiting
Neurocrine Clinical Site
Draper, Utah · Recruiting
Neurocrine Clinical Site
Roanoke, Virginia · Recruiting
Neurocrine Clinical Site
Carlton, Victoria, Australia · Recruiting
Neurocrine Clinical Site
Melbourne, Victoria, Australia · Recruiting
Neurocrine Clinical Site
Parkville, Victoria, Australia · Recruiting
Neurocrine Clinical Site
Sofia, Bulgaria · Recruiting
Neurocrine Clinical Site
Sofia, Bulgaria · Recruiting
Neurocrine Clinical Site
Sofia, Bulgaria · Recruiting
Neurocrine Clinical Site
Sofia, Bulgaria · Recruiting
Neurocrine Clinical Site
Toronto, Canada · Recruiting
Neurocrine Clinical Site
Calgary, Alberta, Canada · Recruiting
Neurocrine Clinical Site
North Vancouver, British Columbia, Canada · Recruiting
Neurocrine Clinical Site
Kingston, Ontario, Canada · Recruiting
Neurocrine Clinical Site
Sherbrooke, Quebec, Canada · Active not recruiting
Neurocrine Clinical Site
Tallinn, Estonia · Recruiting
Neurocrine Clinical Site
Tallinn, Estonia · Recruiting
Neurocrine Clinical Site
Tartu, Estonia · Recruiting
Neurocrine Clinical Site
Milan, Italy · Withdrawn
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.